— Know what they know.
Not Investment Advice

APDN NASDAQ

Applied DNA Sciences, Inc.
1W: -9.3% 1M: -20.4% 3M: -25.3% 1Y: -97.6% 3Y: -100.0% 5Y: -100.0%
$5.62
Last traded 2025-11-03 — delisted
NASDAQ · Healthcare · Medical - Diagnostics & Research · $7.3M mcap · 1M float · 36.33% daily turnover · Short 51% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$7.3M
52W Range2.13-319.95
Volume2,648,596
Avg Volume469,222
Beta0.13
Dividend—
Analyst Ratings
3 Buy 0 Hold 1 Sell
Consensus Buy
Company Info
CEOJames A. Hayward Sc.D.
Employees46
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2003-07-15
Websiteadnas.com
50 Health Sciences Drive
Stony Brook, NY 11790
US
631 840 8800
About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Jantzen Beth A-Award 91,667 — 2023-03-23
Shorrock Clay A-Award 91,667 — 2023-03-23
Murrah Judith A-Award 99,306 — 2023-03-23
SHAMASH YACOV A A-Award 75,099 — 2023-01-25
SHAMASH YACOV A A-Award 46,938 — 2023-01-25

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms